TrialThe Lancet. Haematology2021

Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.

Saad Z Usmani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.